The DOI matches its Crossref record, with a small difference in title or year; 24 of the 24 references it cites were found in a registry or an index.
Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis
Abstract
OBJECTIVE: We sought to determine the factors associated with survival after recurrence of hepatocellular cancer (HCC) after resection and the outcome of our prospectively applied treatment protocol. BACKGROUND: Very little is known about the prognosis of HCC that recurs after resection and the outcomes associated with treatments applied to recurrent tumors. METHODS: A total of 661 HCC patients undergoing resection from January 1988 to January 2011 were reviewed to identify those with recurrence. Single recurrences with preserved liver function, and no portal hypertension were treated with resection. Patients with multiple intrahepatic tumors or poor liver function and no major comorbidities were listed for transplantation. Patients with up to 3 tumors, each 4 cm or smaller, and not eligible for transplantation, received ablation. Patients not eligible for ablation received embolization. Other treatments such as systemic therapy and radiation were used in remaining patients, but not in a systematic manner. RESULTS: Recurrent HCC developed in 356 (54%) patients at a median time of 22 months from primary resection. Median survival from time of recurrence to death was 21 months. Variables independently associated with survival from recurrence included time from primary resection to recurrence, alpha-fetoprotein more than 100 ng/mL at recurrence, recurrent tumor larger than 3 cm, BCLC stage at recurrence, and type of treatment rendered for the recurrence. All variables except treatment modality were significantly correlated with characteristics of the original primary tumor. CONCLUSIONS: Most of the variables associated with outcome after recurrence are linked to the primary tumor at initial presentation. Nevertheless, meaningful survival can be achieved with appropriate treatment of recurrent tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The likelihood of disease recurrence after resection or local ablation remains substantial, ranging from 50% to 70% at 5 years (Table 1); the risk of recurrence is highest during the first 12 months following curative treatment54.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [54]
In the citing paper
“We chose 24 months on the basis of historical cohorts, given that it captured more than 50% of relapses in patients who had undergone liver resection.4”
In the citing paper
“For patients with early-stage hepatocellular carcinoma, liver resection might lead to cure; however, relapse rates can be as high as 70% in the first 5 years following resection.4”
In the citing paper
“patients treated with liver surgery alone in historical cohorts showed a risk of recurrence exceeding 50% at the 24-month timepoint,4”
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Llovet, J. M., Fuster, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510300629 · Cited by 1,708
Imamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
Self-citationPoon, R. T.-P., Fan, S.-T., Lo, C.-M., Liu, C.-L., & Wong, J. (1999) · Annals of Surgery · doi:10.1097/00000658-199902000-00009 · Cited by 550 · cited 1×
“…Repeat resection (27 mo) NA TACE 11.8% TACE (36 mo) Systemic chemotherapy or supportive care 63.3% Systemic chemotherapy or supportive care‡ (MS 7 mo) Poon et al 1999∗ 132 Repeat resection 10% TACE or RFA 68% Systemic chemotherapy 8% Supportive care 9% Repeat Resection (70%, NR) TACE or RFA (26…”
BackgroundInfluentialSala, M., Llovet, J. M., Vilana, R., Bianchi, L., Solé, M., Ayuso, C., Brú, C., & Bruix, J. (2004) · Hepatology · doi:10.1002/hep.20465 · Cited by 447
Resection of hepatocellular cancer ≤2 cm: Results from two Western centers
Roayaie, S., Obeidat, K., Sposito, C., Mariani, L., Bhoori, S., Pellegrinelli, A., Labow, D., Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2013) · Hepatology · doi:10.1002/hep.25832 · Cited by 437
Self-citation
Research works printed but not linked: 1
- Jin, 2014, Transarterial chemoembolization versus surgeryradiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion., J Gastroenterol, 29, 1056
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationMarrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
“The risk of recurrence following resection is up to 70% at 5 years, with the most important predictors being tumor differentiation, micro- and macrovascular invasion, and the presence of satellite nodules.(115,116) Tumor size is not an independent predictor of recurrence, though increasing tumor size is associated wit…”
BackgroundA global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“[162,194] Factors associated with recurrence include older age; male sex; degree of liver dysfunction; and tumor size, number, and grade/differentiation; microvascular and macrovascular invasion; presence of satellite lesions; and AFP level.”
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
“Although resection almost always results in complete removal of the initial tumour (or tumours), HCC recurrence is common (with 5-year rates of 50–70%), particularly in those with multi-nodular disease, microvascular invasion and/or poorly differentiated tumours 196”
Background
Metadata
- Authors
- Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M., & Roayaie, S.
- Affiliations
- Mount Sinai Hospital (US)
- Brookdale University Hospital and Medical Center (US)
- Morristown Medical Center (US)
- Northwell Health (US)
- Corresponding author
- Tabrizian, Parissa
- Schwartz, Myron
- Venue
- Annals of Surgery
- Published
- 2015-05
- Volume
- 261
- Issue
- 5
- Pages
- 947-955
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2333367339
- Cited by
- 903
- References
- 24
- Citations by year
- 2026: 73 · 2025: 130 · 2024: 120 · 2023: 137 · 2022: 136 · 2021: 119 · 2020: 84 · 2019: 51 · 2018: 25 · 2017: 16 · 2016: 6 · 2015: 4
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- hepatocellular carcinoma, tumor recurrence, hepatectomy, survival after recurrence, prognostic factors, alpha-fetoprotein, Barcelona Clinic Liver Cancer staging, liver transplantation, ablation, endovascular embolization, portal hypertension, liver function
- MeSH terms
- Algorithms, Embolization, Therapeutic, Female, Hepatectomy, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Prognosis, Reoperation, Time Factors, Survival Analysis, Liver Transplantation, Ablation Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis. https://app.cochat.ai/papers/10.1097/sla.0000000000000710
- The paper
- Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M., & Roayaie, S. (2015). Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis. Annals of Surgery. https://doi.org/10.1097/sla.0000000000000710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.